Cingulate to Participate in Benzinga All Live Access Event

Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) announced that Chairman and CEO Shane J. Schaffer will participate in a Benzinga All Access event on December 2, 2022, at 10 a.m. CST. The discussion will focus on unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD) and the expansion of Cingulate's Precision Timed Release™ (PTR™) platform into anxiety therapeutics. The event will be live-streamed on Benzinga’s YouTube channel and Cingulate’s website. Cingulate's mission is to develop next-generation treatments that improve patient outcomes in ADHD and potentially anxiety disorders.

KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday December 2, 2022, at 10 a.m. CST.

The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area. Dr. Schaffer will also provide a company overview.

The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.

About Cingulate^® 
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.

Cingulate is headquartered in Kansas City. For more information visit Cingulate.com

Investor Relations 
Thomas Dalton 
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com 
913-942-2301

Matt Kreps
Darrow Associates
mkreps@darrowir.com 
214-597-8200

Media Relations
Melyssa Weible
Elixir Health Public Relations
mweible@elixirhealthpr.com 
201-723-5805

FAQ

What is the date and time of the Benzinga All Access event featuring Cingulate's CEO?

The Benzinga All Access event featuring Cingulate's CEO Shane J. Schaffer will take place on December 2, 2022, at 10 a.m. CST.

Where can I watch the live stream of Cingulate's CEO discussion on ADHD?

You can watch the live stream of Cingulate's CEO discussion on ADHD on Benzinga’s YouTube channel and Cingulate’s website.

What topics will be discussed at the Benzinga event regarding Cingulate?

The event will discuss unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD) and the expansion of Cingulate's PTR platform into anxiety therapeutics.

What is Cingulate's focus regarding drug development?

Cingulate focuses on utilizing its Precision Timed Release™ (PTR™) technology to develop next-generation pharmaceutical products for ADHD and anxiety disorders.

What does Cingulate's Precision Timed Release™ (PTR™) technology do?

Cingulate's Precision Timed Release™ (PTR™) technology is a drug delivery platform designed to improve treatment outcomes for patients with conditions like ADHD.